Clinical Pharmacology and Therapeutics
A Textbook of Clinical Pharmacology and ... - clinicalevidence
A Textbook of Clinical Pharmacology and ... - clinicalevidence
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
224 CARDIAC DYSRHYTHMIAS<br />
• inappropriate sinus tachycardia (e.g. in association with<br />
panic attacks);<br />
• paroxysmal supraventricular tachycardias that are<br />
precipitated by emotion or exercise;<br />
• rapid atrial fibrillation that is inadequately controlled by<br />
digoxin;<br />
• tachydysrhythmias of thyrotoxicosis;<br />
• tachydysrhythmias of phaeochromocytoma, after<br />
adequate α-receptor blockade.<br />
Atenolol is available for intravenous use after myocardial<br />
infarction. Esmolol is a cardioselective β-adrenoceptor antagonist<br />
for intravenous use with a short duration of action (its elimination<br />
half-life is approximately 10 minutes). β-Adrenoceptor<br />
antagonists are given more commonly by mouth when used for<br />
the above indications.<br />
Contraindications <strong>and</strong> cautions<br />
Contraindications include the following;<br />
• asthma, chronic obstructive pulmonary disease;<br />
• peripheral vascular disease;<br />
• Raynaud’s phenomenon;<br />
• uncompensated heart failure (β-blockers are actually<br />
beneficial in stable patients (see Chapter 31), but have to<br />
be introduced cautiously).<br />
Drug interactions<br />
• Beta-blockers inhibit drug metabolism indirectly by<br />
decreasing hepatic blood flow secondary to decreased<br />
cardiac output. This causes accumulation of drugs such as<br />
lidocaine that have such a high hepatic extraction ratio<br />
that their clearance reflects hepatic blood flow.<br />
• Pharmacodynamic interactions include increased negative<br />
inotropic effects with verapamil (if given intravenously<br />
this can be fatal), lidocaine, disopyramide or other<br />
negative inotropes. Exaggerated <strong>and</strong> prolonged<br />
hypoglycaemia occurs with insulin <strong>and</strong> oral<br />
hypoglycaemic drugs.<br />
AMIODARONE<br />
Use<br />
Amiodarone is highly effective, but its use is limited by the<br />
severity of its adverse effects during chronic administration. It<br />
is effective in a wide variety of dysrhythmias, including:<br />
• supraventricular dysrhythmias – resistant atrial fibrillation<br />
or flutter, re-entrant tachycardias (e.g. WPW syndrome);<br />
• ventricular dysrhythmias – recurrent ventricular tachycardia<br />
or fibrillation.<br />
It can be given intravenously, via a central intravenous line, in<br />
emergency situations as discussed above, or orally if rapid<br />
dysrhythmia control is not required.<br />
Mechanism of action<br />
Amiodarone is a class III agent, prolonging the duration of the<br />
action potential but with no effect on its rate of rise.<br />
Adverse effects <strong>and</strong> contraindications<br />
Adverse effects are many <strong>and</strong> varied, <strong>and</strong> are common when<br />
the plasma amiodarone concentration exceeds 2.5 mg/L.<br />
1. Cardiac effects – the ECG may show prolonged QT,<br />
U-waves or deformed T-waves, but these are not in<br />
themselves an indication to discontinue treatment.<br />
Amiodarone can cause ventricular tachycardia of the<br />
variety known as torsades de pointes. Care is needed in<br />
patients with heart failure <strong>and</strong> the drug is contraindicated<br />
in the presence of sinus bradycardia or AV block.<br />
2. Eye – Amiodarone causes corneal microdeposits in almost<br />
all patients during prolonged use. Patients may report<br />
coloured haloes without a change in visual acuity. The<br />
deposits are only seen on slit-lamp examination <strong>and</strong><br />
gradually regress if the drug is stopped.<br />
3. Skin – photosensitivity rashes occur in 10–30% of patients.<br />
Topical application of compounds which reflect both UV-<br />
A <strong>and</strong> visible light can help (e.g. zinc oxide), whereas<br />
ordinary sunscreen does not; <strong>and</strong> patients should be<br />
advised to avoid exposure to direct sunlight <strong>and</strong> to wear a<br />
broad-brimmed hat in sunny weather. Patients sometimes<br />
develop blue-grey pigmentation of exposed areas. This is<br />
a separate phenomenon to phototoxicity.<br />
4. Thyroid – amiodarone contains 37% iodine by weight <strong>and</strong><br />
therefore may precipitate hyperthyroidism in susceptible<br />
individuals; or conversely it can cause hypothyroidism,<br />
due to alterations in thyroid hormone metabolism, with a<br />
rise in thyroxine (T 4 ) <strong>and</strong> reverse tri-iodothyronine (rT 3 ), a<br />
normal or low T 3 <strong>and</strong> a flat thyroid-stimulating hormone<br />
(TSH) response to thyrotropin-releasing hormone (TRH).<br />
Thyroid function (T 3 , T 4 <strong>and</strong> TSH) should be assessed<br />
before starting treatment <strong>and</strong> annually thereafter, or more<br />
often if the clinical picture suggests thyroid dysfunction.<br />
5. Pulmonary fibrosis – may develop with prolonged use. This<br />
potentially serious problem usually but not always<br />
improves on stopping the drug.<br />
6. Hepatitis – transient elevation of hepatic enzymes may<br />
occur <strong>and</strong> occasionally severe hepatitis develops. It is<br />
idiosyncratic <strong>and</strong> non-dose-related.<br />
7. Peripheral neuropathy – occurs in the first month of<br />
treatment <strong>and</strong> reverses on stopping dosing. Proximal<br />
muscle weakness, ataxia, tremor, nightmares, insomnia<br />
<strong>and</strong> headache are also reported.<br />
Pharmacokinetics<br />
Amiodarone is variably absorbed (20–80%) when administered<br />
orally. However, both the parent drug <strong>and</strong> its main<br />
metabolite, desethyl amiodarone (the plasma concentration of<br />
which exceeds that of the parent drug), are highly lipid soluble.<br />
This is reflected in a very large volume of distribution<br />
(approximately 5000 L). It is highly plasma protein bound<br />
(over 90%) <strong>and</strong> accumulates in all tissues, particularly the<br />
heart. It is only slowly eliminated via the liver, with a t 1/2 of<br />
28–45 days. Consequently, anti-dysrhythmic activity may continue<br />
for several months after dosing has been stopped, <strong>and</strong> a<br />
loading dose is needed if a rapid effect is needed.